The Department of Justice on Wednesday took a crack at dismantling AstraZeneca’s lawsuit over the selection of its type 2 diabetes drug Farxiga (dapagliflozin) for drug price negotiations, saying it “fares no better than the others.”
AstraZeneca, which filed its complaint in Delaware federal court in August, contested two…
Click here to view original post
